

TEST REQUISITION FORM

SOLID ONCOLOGY

/	NT DETAILS
/ (In B	LOCK letters)
Full Name	
Y Y M M Age // / Gender M	F Ethnicity
E-mail ID	Contact No.
Address	
City / State / Postal Code	Country Country
REFERRII	NG CLINICIAN —
Physician Name	
Facility Name	
Facility Address	
City / State / Postal Code	Country Country
E-mail ID	Contact No.
Additional Physician to be Copied(optional)	
Facility Name	
E-mail ID	Contact No.
CLINIC	AL DETAILS —
Diagnosis : □ NSCLC □ Melanoma □ Co	olorectal Adenocarcinoma 🗆 Ovarian 🗆 Breast
□ Other	
Disease Status (select as many as apply): Metasta	
Subtype Badiological Findings :	Stage Stage
Radiological Findings :	
ER, PR, Her2 /Neu Status :	
Previous Genetic Tests /Targeted Therapies (if any)/	
Please attach the below reports to the TRF : (if Availa	able)
Attachments : ☐ Copy of recent Pathology /Cytology reports	
	says by FISH, IHC, or other genetic assays, e.g.,ER, PR,
HER2, EGFR, KRAS,etc.	

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059 Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com



TEST REQUISITION FORM

	TEST SELECTION (Sample Type)			
OncoC	CEPT Solid (*FFPE block co	ntaining tumor tissue)	OncoCEPT Liquid (*10ml Whole blood EDTA in streck tube)	
OncoCEPT Comprehensive (*FFPE block containing tumor tissue)		FFPE block containing tumor tissue)	MSI (*FFPE blocks with slides + EDTA blood)	
ColoCo	omprehensive (MSI+BI	RAF+KRAS+NRAS) (*FFPE bl	ock containing tumor tissue) MMR by IHC	
PDL-1	test PDL1 SP	142 PDL1 SP 263	PDL1 22C3 DAKO (#Drug details)	
OncoC	CEPT Solid + PDL1		OncoCEPT Solid Comprehensive + PDL1	
Other	test : Description of te	est & sample type		
OncoC		CEPT Solid Comprehensive	ich test would you like us to do first:	
# Drug d (PDL-1 IHC clone scoring	DEPT Solid Oncoo	ecific tumor type in order to predictive irements are dependent on the tu	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and sp	
# Drug d (PDL-1 IHC clone scoring	GEPT Solid Oncoc	ecific tumor type in order to predicirements are dependent on the tu	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and sp	
# Drug d (PDL-1 IHC clone scoring	DEPT Solid Oncoo	ecific tumor type in order to predictive irements are dependent on the tu	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and sp	
# Drug d (PDL-1 IHC clone scoring	DEPT Solid Oncoo	ecific tumor type in order to predictive ments are dependent on the tumor type. Clone Sp263	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and spontage of malignancy previous treatment outcomes are previous treatment outcomes and spontage of malignancy previous treatment outcomes are previous treatment outcomes and treatment outcomes are previous treatment outcomes	
# Drug d (PDL-1 IHC clone scoring	DEPT Solid Oncoo	ecific tumor type in order to predictive ments are dependent on the tumor type in sp263 Sp263	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and spontage of malignancy previous treatment outcomes are previous treatment outcomes and spontage of malignancy previous treatment outcomes are pre	
# Drug d (PDL-1 IHC clone scoring	DEPT Solid Oncoo	ecific tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent on the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to predictive ments are dependent or the tumor type in order to pre	PDL-1 It their responses to treatment with PDL-1 inhibitors. The specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of malignancy, previous treatment outcomes and specific PI mor type, stage of	

Date of Collection (MM/DD/YYYY) FFPE of tumour tissue (BIOPSY fixed in 10% Neutral buffered formalin) Specimen Site No. of paraffin blocks and details: Please mention block number on which test has to be performed Body Fluid (At least 1 litre) or cell block FFPE BLOCK of tumor tissue (BIOPSY fixed in 10% Neutral buffered formalin) with HE stained slide Specimen Site Unstained poly L lysine coated slides Cold ischaemia time - mins or hrs or unknown (As time of transfer of tissue after removal from body upto immersion into the 10% neutral buffered formalin) Time Formalin fixation (10% neutral buffered formalin): known: hours / unknown Please Note: Neuberg Center for Genomic Medicine (NCGM) chooses the best block(s) based on initial morphologic assessment for further IHC PDL- 1

—— SAMPLE DETAILS ————

- study. It makes all efforts to preserve and makes sure not to exhaust the tissue entirely under study. However in small thin/tiny specimen, there is a possibility of exhausting the tissue to ensure quality and reliability of the results.
- CAP/ASCO recommendation: for breast markers and GI Her2neu, the cold ischemic time should be < 01 hours and optimal fixation for ER/PgR/Her2Neu in 10% buffered formalin MUST be 06 to 72 hours

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059 Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com



TEST REQUISITION FORM

Family History of any Cancer

Sr. No.	Type of Cancer	Age of diagnosis	Relationship with patient	Mother's or father's side	Histopathology / genetic test reports (if available)

PHYSICIAN CONSENT

I certify that I am patient's treating physician and I consent that this test will aid in patient's ongoing treatment.
I have explained the patient about nature and purpose of testing. Patient has given his consent to me for
Neuberg Center for Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature	Printed Name	Date: DD/MM/YY

PATIENT CONSENT

I certify that I have been explained by my physician that this test will aid in my ongoing treatment/management. I have been explained about nature and purpose of testing. I give my consent to Neuberg Center of Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature	Printed Name	Date: DD/MM/YY

Neuberg Centre for Genomic Medicine (NCGM)

Near GTPL House, Opp. Armedia, Sindhu Bhavan Road, Bodakdev, Ahmedabad 380059 Phone: +91-6357244307, 079-61618111 | Email: contact@ncgmglobal.com | Web: www.ncgmglobal.com